Inodilator therapy in pediatric septic shock

Pediatric Critical Care Medicine

Volumn 2, Issue 1, 2001, Pages 102-104

  Silver, Peter ^a  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

Amrinone; Milrinone; Pediatrics; Phosphodies terase inhibitors; Septic shock

Indexed keywords

EID: 33947096782     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/00130478-200101000-00020     Document Type: Editorial

References (38)

1. Cunnion R, Parrillo J: Myocardial dysfunction in sepsis—recent insights. Chest 1989; 95: 941-948
2. Parrillo J, Burch C, Shelhamer J, et al: A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depressed in vitro myocardial cell performance. J Clin Invest 1985; 76: 1539-1553
3. Kumar A, Thota V, Dee L, et al: Tumor necrosis factor-alpha and interleukin-1 beta are responsible for in vitro myocardial cell depression induced by human shock serum. J Exp Med 1996; 183: 949-958
4. Carpati C, Astiz M, Rackow E: Mechanisms and management of myocardial dysfunction in septic shock (editorial). Crit Care Med 1999; 27: 231-232
5. Parrillo J: Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-1477
6. Giroir B, Stromberg D: Myocardial depression versus myocardial destruction: Integrating the multiple mechanisms of myocardial dysfunction during sepsis (editorial). Crit Care Med 2000; 28: 3111-3112
7. Cunnion RE, Schaer GL, Parker M, et al: The coronary circulation in septic shock. Circulation 1986; 73: 637-644
8. Solomon M, Correa R, Alexander H, et al: Myocardial energy metabolism and morphology in a canine model of sepsis. Am J Physiol 1994; 266: H757-H768
9. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine: Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999; 27: 639-660
10. Marik P, Varon J: The hemodynamic derangements in sepsis: Implications for treatment strategies. Chest 1998; 114: 854-860
11. Davies M, Hagen P: Systemic inflammatory response syndrome. Br J Surg 1997; 84: 920-935
12. Ceneviva G, Paschall J, Maffei F, et al: Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998; 102: 391
13. Ryding J, Heslet L, Hartvig T, et al: Reversal of ‘refractory septic shock’ by infusion of amrinone and angiotensin II in an anthracycline-treated patient. Chest 1995; 107: 210-203
14. Alousi A, Johnson D: Pharmacology of the bipyridines: amrinone and milrinone. Circulation 1986; 73: 111-124
15. Young R, Ward A: Milrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs 1988; 36: 158-192
16. Lindsay C, Barton P, Lawless S, et al: Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr 1998; 132: 329-334
17. Earl C, Linden J: Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone. J Cardiovasc Pharmacol 1986; 8: 864-872
18. Barton P, Garcia J, Kouatli A, et al: Hemodynamic effects of IV milrinone lactate in pediatric patients with septic shock. Chest 1996; 109: 1302-1312
19. Lawless S, Burkhart G, Diven W, et al: Amrinone in neonates and infants after cardiac surgery. Crit Care Med 1989; 17: 751-754
20. Sorenson G, Ramamoorthy C, Lynn A, et al: Hemodynamic effects of amrinone and colloid administration in children following cardiac surgery. J Cardiothorac Anesth 1993; 7: 560-565
21. Bailey J, Miller B, Kanter K, et al: A comparison of the hemodynamic effects of amrinone and sodium nitroprusside in infants after cardiac surgery. Anesth Analg 1997; 84: 294-298
22. Bailey J, Miller B, Lu W, et al: The pharmacokinetics of milrinone in pediatric patients after cardiac surgery. Anesthesiology 1999; 90: 1012-1018
23. Irazuzta J, Pretzlaff R, Rowin M: Amrinone in pediatric septic shock: An open label pharmacodynamic study. Ped Crit Care Med 2001; x:xxx-yyy.
24. Honerjager P: Pharmacology of bipyridine phosphodiesterase III inhibitors. Am Heart J 1991; 121: 1939-1944
25. Anderson J, Baim D, Fein S, et al: Efficacy and safety of sustained intravenous infusions of milrinone in patients with severe congestive heart failure: A multicenter study. J Am Coll Cardiol 1987; 9: 711-722
26. Edelson J, Stroshane R, Benziger D, et al: Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation 1986; 73 (suppl. 3): 145-152
27. Kumar A, Kosuri R, Kandula P, et al: Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor-alpha exposed cardiac myocytes. Crit Care Med 1999; 27: 286-292
28. Giroir B, Beutler B: Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock 1992; 36: 200-207
29. Russell J: Adding fuel to the fire: The supranormal oxygen delivery trials controversy (editorial). Crit Care Med 1998; 26: 981-983
30. Shoemaker W, Appel P, Kram H, et al: Prospective trial of supranormal values of survivors as therapeutic goals in high risk patients. Chest 1988; 94: 1176-1186
31. Boyd O, Grounds R, Bennet D: A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high risk surgical patients. JAMA 1993; 270: 2699-2707
32. Bishop M, Shoemaker W, Appel P, et al: Prospective randomized trial of survivor values of cardiac index, oxygen delivery and oxygen consumption as resuscitation endpoints in severe trauma. J Trauma 1995; 38: 780-787
33. Yu M, Burchell S, Hasaniya N, et al: Relationship of mortality to increasing oxygen delivery in patients greater than 50 years of age: A prospective, randomized trial. Crit Care Med 1998; 26: 1011-1019
34. Fleming A, Bishop M, Shoemaker W, et al: Prospective trial of supranormal values as goals of resuscitation in severe trauma. Arch Surg 1992; 127: 1175-1181
35. Tuchschmidt J, Fried J, Swinney R, et al: Early hemodynamic correlates of survival in patients with septic shock. Chest 1989; 17: 719-723
36. Yu M, Levy M, Smith P, et al: Effect of max-imizing oxygen delivery on morbidity and mortality rates in critically ill patients: A prospective randomized controlled study. Crit Care Med 1993; 21: 830-838
37. Gattinoni L, Brazzi L, Pelosi P, et al: A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333: 1025-1032
38. Hayes M, Timmins A, Yau E, et al: Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330: 1711-1722